{
    "root": "ec7b676c-3133-d41d-010d-325b76c779b4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ziprasidone hydrochloride",
    "value": "20250307",
    "ingredients": [
        {
            "name": "ZIPRASIDONE HYDROCHLORIDE",
            "code": "216X081ORU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10119"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "ziprasidone capsules indicated treatment schizophrenia , monotherapy acute treatment bipolar manic mixed episodes , adjunct lithium valproate maintenance treatment bipolar disorder . deciding among alternative treatments available condition needing treatment , prescriber consider finding ziprasidone \u2019 greater capacity prolong qt/qtc interval compared several antipsychotic drugs [ ( 5.3 ) ] . prolongation qtc interval associated drugs ability cause torsade de pointes-type arrhythmia , potentially fatal polymorphic ventricular tachycardia , sudden death . many cases would lead conclusion drugs tried first . whether ziprasidone cause torsade de pointes increase rate sudden death yet known [ ( 5.3 ) ] . schizophrenia ziprasidone capsules indicated treatment schizophrenia adults [ ( 14.1 ) ] . bipolar disorder ( acute mixed manic episodes maintenance treatment adjunct lithium valproate ) ziprasidone capsules indicated monotherapy acute treatment adults manic mixed episodes associated bipolar disorder [ ( 14.2 ) ] . ziprasidone capsules indicated adjunct lithium valproate maintenance treatment bipolar disorder adults [ ( 14.2 ) ] .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute mixed manic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_519"
            },
            {
                "disease": "acute treatment bipolar",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_79276"
            },
            {
                "disease": "acute treatment adults",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "contraindications": {
        "text": "administer capsules orally food . open , crush , chew . ( 2.1 ) schizophrenia : initiate 20 mg twice daily . daily may adjusted 80 mg twice daily . dose adjustments occur intervals less 2 days . safety efficacy demonstrated doses 100 mg twice daily . lowest effective dose used . ( 2.2 ) acute treatment manic/mixed episodes bipolar disorder : initiate 40 mg twice daily . increase 60 mg 80 mg twice daily day 2 treatment . subsequent dose adjustments based tolerability efficacy within range 40 80 mg twice daily . ( 2.3 ) maintenance treatment bipolar disorder adjunct lithium valproate : continue treatment dose patient initially stabilized , within range 40 80 mg twice daily . ( 2.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ziprasidone capsules , usp differentiated capsule color/size imprinted black ink \u201c apo zip \u201d unique number . ziprasidone capsules , usp supplied oral 20 mg ( purple/white ) , 40 mg ( purple/purple ) , 60 mg ( white/white ) , 80 mg ( purple/white ) capsules . supplied following strengths package configurations : ziprasidone capsules package configuration capsule strength ( mg ) ndc ( national code ) imprint bottles 60 20 ndc-60505-2528-6 apo zip 20 bottles 60 40 ndc-60505-2529-6 apo zip 40 bottles 60 60 ndc-60505-2530-6 apo zip 60 bottles 60 80 ndc-60505-2531-6 apo zip 80 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container [ usp ] .",
    "adverseReactions": "patients known history qt prolongation ( 4.1 ) patients recent acute myocardial infarction ( 4.1 ) patients uncompensated heart failure ( 4.1 ) combination drugs demonstrated qt prolongation ( 4.1 ) patients known hypersensitivity ziprasidone ( 4.2 ) concomitant monoamine oxidase inhibitors ( maois ) , within 14 days stopping maois . ( 4.3 )",
    "indications_original": "Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.\u00a0When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone\u2019s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see \n                     \n                     Warnings and Precautions (5.3)].\u00a0 Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see\n                      Warnings and Precautions (\n                     \n                        5.3\n                     \n                     )]. \n                  \n                     Schizophrenia\n                  \n                  \n                     Ziprasidone capsules are indicated for the treatment of schizophrenia in adults [see Clinical Studies (14.1)].\n                     \n                  \n                  \n                     Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate)\n                  \n                  \n                     Ziprasidone capsules are indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies (14.2)].\n                     \n                     Ziprasidone capsules are indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies (14.2)].",
    "contraindications_original": "Administer capsules orally with food. Do not open, crush, or chew. ( 2.1 ) Schizophrenia: Initiate at 20 mg twice daily. Daily dosage may be adjusted up to 80 mg twice daily. Dose adjustments should occur at intervals of not less than 2 days. Safety and efficacy has been demonstrated in doses up to 100 mg twice daily. The lowest effective dose should be used. ( 2.2 ) Acute treatment of manic/mixed episodes of bipolar I disorder: Initiate at 40 mg twice daily. Increase to 60 mg or 80 mg twice daily on day 2 of treatment. Subsequent dose adjustments should be based on tolerability and efficacy within the range of 40 to 80 mg twice daily. ( 2.3 ) Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate: Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 to 80 mg twice daily. ( 2.3 )",
    "warningsAndPrecautions_original": "Ziprasidone capsules, USP are differentiated by capsule color/size and are imprinted in black ink with \u201cAPO ZIP\u201d and a unique number. Ziprasidone capsules, USP are supplied for oral administration in 20 mg (purple/white), 40 mg (purple/purple), 60 mg (white/white), and 80 mg (purple/white) capsules. They are supplied in the following strengths and package configurations:\n                  \n                     \n                        \n                           Ziprasidone Capsules\n                        \n                        \n                           Package Configuration\n                           Capsule Strength (mg)\n                           NDC (National Drug Code)\n                           Imprint\n                        \n                        \n                           Bottles of 60\n                           20\n                           NDC-60505-2528-6\n                           APO ZIP 20\n                        \n                        \n                           Bottles of 60\n                           40\n                           NDC-60505-2529-6\n                           APO ZIP 40\n                        \n                        \n                           Bottles of 60\n                           60\n                           NDC-60505-2530-6\n                           APO ZIP 60\n                        \n                        \n                           Bottles of 60\n                           80\n                           NDC-60505-2531-6\n                           APO ZIP 80\n                        \n                     \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted from 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container [see USP].",
    "adverseReactions_original": "Do not use in patients with a known history of QT prolongation ( 4.1 ) Do not use in patients with recent acute myocardial infarction ( 4.1 ) Do not use in patients with uncompensated heart failure ( 4.1 ) Do not use in combination with other drugs that have demonstrated QT prolongation ( 4.1 ) Do not use in patients with known hypersensitivity to ziprasidone ( 4.2 ) Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. ( 4.3 )",
    "drug": [
        {
            "name": "ziprasidone hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10119"
        }
    ]
}